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Objectives: To evaluate lipid profile parameters in patients with various grades of non-alcoholic fatty liver 
disease (NAFLD) diagnosed on sonography. 
Material and Method: This descriptive cross-sectional study was conducted at HBS General Hospital, Islamabad 
over a period of six months from January 2018 to June 2018. Seventy-nine adults of either gender diagnosed with 
NAFLD on ultrasonography were consecutively included. Fasting blood sample of all the subjects was analyzed 
for total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and high-density 
lipoprotein cholesterol (HDL-C) Comparison of lipid abnormalities between different grades of NAFLD was done 
by statistical analysis with p-value <0.05 considered statistically significant. 
Results: Out of the total 79 patients, grade I, II, and III NAFLD was diagnosed in 56.6%, 45.5%, and 3.9% 
respectively. Total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C) were raised in 
28 (35.4%), 43 (54.4%) and 43 (54.4%) patients respectively. Low serum high-density lipoprotein cholesterol (HDL-
C) levels were seen in 74 (93.6%) of patients. Statistical analysis showed a significant increase in frequency as well 
as mean values in all serum lipid profile parameters with the severity of NAFLD grades except total cholesterol 
(TC).  
Conclusion: Increasing grades of NAFLD showed a significant correlation with higher levels of cholesterol, LDL, 
and decreasing levels of HDL, which are all associated with cardiovascular problems.  
Keywords:  Non-alcoholic fatty liver disease; Dyslipidemia; Metabolic syndrome.  




An extensive array of chronic hepatic disorders 
varying from plain steatosis to steatohepatitis (NASH) 
with enhanced fibrotic and cirrhotic changes on 
histology without considerable alcohol use defines 
non-alcoholic fatty liver disease.1,2 
The number of fatty liver patients has risen over the 
past two decades due to an increase in overweight, 
obese individuals and their consequent metabolic 
derangements, possibly due to an unhealthy and 
sedentary lifestyle.3,4,5 The global prevalence rate of 
NAFLD is 25.24%. As per the World Gastroenterology 
Organization Global Guidelines 2014, the NAFLD 
prevalence rate in the Pakistani population is 18%.6,7,8 
Fatty liver is linked with metabolic risk factors. 
Observational studies revealed that NAFLD patients 
exhibit a greater possibility of evolving complications 
that are extrahepatic, like metabolic syndrome, 
cardiovascular disease, and diabetes.7,8,9 It is 
postulated that deposition of lipids, primarily 
triacylglycerol (TAG) in the hepatic cells is the main 
element of the pathogenesis of NAFLD, however, the 
exact mechanism is still unclear.10,11 NAFLD is linked 
with raised values of VLDL, TG, and LDL with 
decreased values of serum HDL which can lead to 
cardiovascular diseases (CVD) morbidity and 
mortality.12,13,14 
 Liver biopsy is the most precise procedure for 
diagnosing NAFLD, but it is an uncomfortable and 
invasive method with uncommon potentially serious 
complications. It is prone to sampling errors.15,16,17 
Thus, an ultrasonography based classification system 
is recognized that relates histologic aspects with 
prognosis.16 
Our study aims at determining the correlation of 
different lipid profile parameters with the grading of 
NAFLD as shown on ultrasound. This will aid in the 
earlier detection of dyslipidemias and effective 
management in the times to come.  
 
Materials and Methods 
 
This cross-sectional study was conducted at the 
Department of Radiology and the Department of 
Medicine, HBS General Hospital, Islamabad from 
January 2018 to June 2018. The study was approved by 
the institution’s research ethics committee. The study 
included 79 patients of either gender aged 18 years or 
above, diagnosed with non-alcoholic fatty liver disease 
(NAFLD) on ultrasonography, using non-probability 
consecutive sampling. Patients with a history of 
alcohol consumption, viral and autoimmune hepatitis, 
and those using lipid-lowering medicines were 
excluded. Pregnant patients were also excluded. The 
ultrasound examination was done on Toshiba Xario 
using a 5MHz probe. The hepatic steatosis was graded 
according to the following criteria,  
 Grade I: increased liver echogenicity with 
normal periportal and diaphragmatic 
echogenicity.  
 Grade II: increased liver echogenicity with 
imperceptible periportal echogenicity without 
obscuration of the diaphragm.  
 Grade III: increased liver echogenicity with 
imperceptible periportal echogenicity and 
obscuration of the diaphragm.  
Patients were informed about the aims and design of 
the study and consent was taken individually. 3ml of 
blood samples were taken from the study participants 
after an overnight fast and analyzed for serum TC, TG, 
HDL, and LDL. Dyslipidemias were defined according 
to the AACE 2017 guidelines for the management of 
dyslipidemia and prevention of atherosclerosis as 
follows: High TC>200 mg/ml; High TG>150 mg/ml; 
High LDL-C>100 mg/ml; and Low HDL-C<40 
mg/ml. The demographic and the clinical data were 
entered in a pre-designed proforma and analyzed 
using Statistical Package for Social Sciences (SPSS). 
Results were reported as mean ± standard deviation 
(SD) for continuous variables and as frequencies for 
categorical variables. Frequencies of dyslipidemias 
and mean values of individual lipids in different 
grades of NAFLD were statistically compared using 




79 patients of NAFLD were included in the study out 
of which 7 (8.9%) were males and 72 (91.9%) were 
females. The mean age was calculated to be 42.2 years. 
Fatty liver grades in the patients detected by 
sonography are given in Figure 1 while the laboratory 
findings of the study participants are given in Table 1.  
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Figure 1: Grades of NAFLD in the study patients on 
the basis of ultrasound 
 














































Analysis of the laboratory parameters of the study 
participants showed abnormally raised serum TG, TC, 
and LDL-C in 54.4%, 35.4%, and 54.4% of the 
participants respectively, while low serum HDL-C was 
observed in 93.7% of the study subjects as shown in 
Figure 2. The Chi-square test performed showed a 
significant difference in the various grades of NAFLD 
for the frequency of dyslipidemia in all lipid profile 
parameters except serum TC (p-value= 0.183) as 




Figure 2: Frequency of dyslipidemias in the patients 
of NAFLD 
  












Serum Total Cholesterol 
(>200 mg/dL) 
28 (35.4) 7 (25) 18 (64) 3 (10) 0.183 
Serum Triglycerides 
(>150 mg/dL) 
43 (54.4) 17 (39.5) 23 (53.4) 3 (0.06) 0.077 
Serum HDL-Cholesterol 
(<40 mg/dL) 
74 (93.6) 38 (51) 33 (44.5) 3 (0.04) 0.007 
Serum LDL-Cholesterol 
(>100 mg/dL) 
43 (54.4) 18 (41.8) 23 (53.4) 2 (0.04) 0.037 
 
The ANOVA test performed, revealed a significant association of rising grades of NAFLD with rising mean 
values of dyslipidemias in all lipid profile parameters except serum TC (p-value= 0.99) as evident in Table 3.  
 




Mean ± SD 
Grade-I 
Mean ± SD 
Grade-II 
Mean ± SD 
Grade-III 
Mean ± SD 
Anova 
Serum Total Cholesterol 178.78 ± 37.60 167.55 ± 31.267 189.1 ± 41.5 205 ± 21.93 0.099 
Serum Triglycerides 196.28 ± 79.65 190 ± 85 199 ± 63 278 ±107 0.047 
Serum HDL-Cholesterol 33.81 ± 5.71 33 ± 5 35 ± 7 32 ± 4 0.040 
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Discussion 
 
Common metabolic aberrations like obesity, 
hyperglycemia, dyslipidemia, and hypertension are 
known as major health risk factors worldwide leading 
to an increase in hepatic steatosis regardless of age and 
gender.7 
Being the major focus of this study, the association of 
dyslipidemias with various grades of NAFLD was 
evaluated. 
The age of patients varied from 23 to 65 years, the 
mean being 42.2 in our study. Many studies have 
stated 41-45 years as the mean age of fatty liver 
disease. Thus, the above forty years age group is at a 
significantly higher risk of developing NAFLD as they 
may be more prone to metabolic abnormalities 
including dyslipidemias due to deposition of fats. A 
study by Goh et al on the Asian population in 
Malaysia also reported this.19  
In our study 54.4% (43) of all NAFLD patients had 
hypertriglyceridemia. Increased levels of serum TC, 
LDL-C, and decreased levels of serum HDL were 
present in 35.4% (28), 54.4% (43), and 93.7% (74) 
respectively of all NAFLD subjects. 
Dyslipidemia among NAFLD patients has been 
studied and compared with healthy subjects in various 
studies.20 Mahaling et al. (2013) and Bano et al. (2008) 
showed hypertriglyceridemia as the commonest 
dyslipidemia, and the next common dyslipidemia was 
low HDL-C. Nevertheless, in our study, the most 
significant dyslipidemia was low HDL-C (93.7%). 
The pathogenesis of NAFLD is poorly understood but 
variation in oxidant systems or body fat distribution, 
most likely due to a genetic predilection may be 
amongst the explanation. 
A total accumulation of fats within hepatocytes 
commonly TG leads to the development of the fatty 
liver. Lipid accumulation and the preceding principal 
metabolic defects are not fully comprehended. A 
possible explanation is derangements in hepatic 
triglyceride metabolism pathways due to insulin 
resistance. The most reproducible factor for fatty liver 
disease occurrence in diabetics is insulin resistance.22,23 
NASH and NAFLD are commonly identified 
parenthetically or in concurrence with different co-
morbidities like obesity. As the prevalence of the fatty 
liver disease is rising,7,8 and corresponds with the 
metabolic syndrome, clinical practice guidelines now 
propose that all obese or diabetic patients should be 
scrutinized for NAFLD. 
Our study showed that 32.9% (26) patients with 
NAFLD were diabetic, 27.8% (22) were overweight, 
55.7% (44) were obese, 5.1% (4) were morbidly obese 
and 11.4% (9) had normal BMI. 
Biopsy (liver) is the most sensitive test in identifying 
hepatic steatosis, but as it is an invasive procedure 
causing pain with associated complications and 
sampling errors, it is not appropriate for asymptomatic 
subjects. 
Thus keeping this view, ultrasonography offers a 
favorable alternative to diagnose fatty liver disease. 
This is proven by statistically significantly deranged 
lipid profile parameters in this study. 
The specificity and sensitivity of sonographic detection 
are high (83.9% and 84.6% respectively) in higher 
grades of steatosis. Sonography is a cheaper safe 
modality for early detection of NAFLD thus 
minimizing invasive investigations in these patients. 
There were a few limitations to our study. 
Ultrasonography based detection of NAFLD and its 
grading cannot detect cases of mild steatosis for which 
liver biopsy is the gold standard. The study cohort 
may not be representative of all the major ethnic 
groups of Pakistan, so a bigger multi-racial, case-
control study design using liver biopsy to identify and 




Results in our study lead to the conclusion of a 
significant correlation between increasing grades of 
NAFLD and increased frequency of dyslipidemias. 
The most frequent dyslipidemia being low HDL-C 
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